Athena Athena

X
[{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Serums to assess sepsis drug Ulinastatin for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Jagdale Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bharat Serums and Vaccines Acquires Key Women Health Brand Tidilan from Jagdale Industries","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Bharat Serums & Vaccines ltd

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Tidilan is currently available in tablet and injectable dosage forms. BSV has some of the leading women’s health brands such as Rhoclone, Hucog, Hucog 5000 HP, AntiD among others.

            Lead Product(s): Isoxsuprine Hydrochloride

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Tidilan

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Jagdale Industries

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition April 05, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The trial will involve approximately 120 patients who have mild to moderate symptoms of acute ARDS. The drug is expected to improve recovery time and also mitigate mortality rates.

            Lead Product(s): Urinastatin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY